We are live on
!
Find out more
Inovio Pharmaceuticals
100 hedge funds and large institutions have $54.6M invested in Inovio Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
138% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $469K
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
5% less capital invested
Capital invested by funds: $57.5M → $54.6M (-$2.87M)
2% less funds holding
Funds holding: 102 → 100 (-2)
2.68% less ownership
Funds ownership: 48.07% → 45.4% (-2.7%)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
Holders
100
Holders Change
-2
Holders Change %
-1.96%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
19
Reduced
23
Closed
15
Calls
$1.12M
Puts
$469K
Net Calls
+$649K
Net Calls Change
-$1.21M
Top Buyers
| 1 |
EP
Eversept Partners
New York
|
+$1.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$471K |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
+$208K |
| 4 |
Renaissance Technologies
New York
|
+$149K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$130K |
